Arctic Bioscience AS’ Annual General Meeting will be held Friday 21 April 2023 at 14:00 (CET), as a digital meeting.
Shareholders are encouraged to cast their votes in advance of the General Meeting or grant the Chair of the Board a proxy, with or without voting instructions.
Deadline for registration of attendance, advance votes, proxy or instructions is 20 April 2023 at 14:00 (CET). For attendance to the live event, please follow the instruction in the notice.
For further information, see the attached Notice of the Annual General Meeting, which can also be accessed from the company’s website (https://arctic-bioscience.com/investors/general-meetings/).
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact:
Christer L. Valderhaug
Phone: +47 920 84 601
Jone R. Slinning
Mobile: +47 948 75 469
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.